These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31861119)

  • 1. Site-Specific
    Lumen D; Näkki S; Imlimthan S; Lambidis E; Sarparanta M; Xu W; Lehto VP; Airaksinen AJ
    Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pore Size and Surface Chemistry of Porous Silicon Particles and Structure of Phospholipids on Their Interactions.
    Liu D; Lipponen K; Quan P; Wan X; Zhang H; Mäkilä E; Salonen J; Kostiainen R; Hirvonen J; Kotiaho T; Santos HA
    ACS Biomater Sci Eng; 2018 Jul; 4(7):2308-2313. PubMed ID: 30159385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored Dual PEGylation of Inorganic Porous Nanocarriers for Extremely Long Blood Circulation in Vivo.
    Nissinen T; Näkki S; Laakso H; Kučiauskas D; Kaupinis A; Kettunen MI; Liimatainen T; Hyvönen M; Valius M; Gröhn O; Lehto VP
    ACS Appl Mater Interfaces; 2016 Dec; 8(48):32723-32731. PubMed ID: 27934159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
    Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
    Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional porous silicon nanoparticles for cancer theranostics.
    Wang CF; Sarparanta MP; Mäkilä EM; Hyvönen ML; Laakkonen PM; Salonen JJ; Hirvonen JT; Airaksinen AJ; Santos HA
    Biomaterials; 2015 Apr; 48():108-18. PubMed ID: 25701036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved stability and biocompatibility of nanostructured silicon drug carrier for intravenous administration.
    Näkki S; Rytkönen J; Nissinen T; Florea C; Riikonen J; Ek P; Zhang H; Santos HA; Närvänen A; Xu W; Lehto VP
    Acta Biomater; 2015 Feb; 13():207-15. PubMed ID: 25463492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
    Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
    Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
    Kovalainen M; Mönkäre J; Mäkilä E; Salonen J; Lehto VP; Herzig KH; Järvinen K
    Pharm Res; 2012 Mar; 29(3):837-46. PubMed ID: 22033881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
    Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X
    Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart.
    Tölli MA; Ferreira MP; Kinnunen SM; Rysä J; Mäkilä EM; Szabó Z; Serpi RE; Ohukainen PJ; Välimäki MJ; Correia AM; Salonen JJ; Hirvonen JT; Ruskoaho HJ; Santos HA
    Biomaterials; 2014 Sep; 35(29):8394-405. PubMed ID: 24985734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facile method to radiolabel glycol chitosan nanoparticles with (64)Cu via copper-free click chemistry for MicroPET imaging.
    Lee DE; Na JH; Lee S; Kang CM; Kim HN; Han SJ; Kim H; Choe YS; Jung KH; Lee KC; Choi K; Kwon IC; Jeong SY; Lee KH; Kim K
    Mol Pharm; 2013 Jun; 10(6):2190-8. PubMed ID: 23586421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PEG-assisted membrane coating to prepare biomimetic mesoporous silicon for PET/CT imaging of triple-negative breast cancer.
    Wen H; Martínez MG; Happonen E; Qian J; Vallejo VG; Mendazona HJ; Jokivarsi K; Scaravilli M; Latonen L; Llop J; Lehto VP; Xu W
    Int J Pharm; 2024 Mar; 652():123764. PubMed ID: 38176479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bisphosphonate ligands and PEGylation on targeted delivery of gold nanoparticles for contrast-enhanced radiographic detection of breast microcalcifications.
    Cole LE; McGinnity TL; Irimata LE; Vargo-Gogola T; Roeder RK
    Acta Biomater; 2018 Dec; 82():122-132. PubMed ID: 30316022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
    Choi KY; Min KH; Yoon HY; Kim K; Park JH; Kwon IC; Choi K; Jeong SY
    Biomaterials; 2011 Mar; 32(7):1880-9. PubMed ID: 21159377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography.
    Sarparanta M; Mäkilä E; Heikkilä T; Salonen J; Kukk E; Lehto VP; Santos HA; Hirvonen J; Airaksinen AJ
    Mol Pharm; 2011 Oct; 8(5):1799-806. PubMed ID: 21875120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of surface grafting density of PEG macromolecules on dually fluorescent silica nanoparticles used for the in vivo imaging of subcutaneous tumors.
    Adumeau L; Genevois C; Roudier L; Schatz C; Couillaud F; Mornet S
    Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1587-1596. PubMed ID: 28179102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study.
    Fresacher K; Helbok A; Reiser M; Blass S; Rangger C; Mair C; von Guggenberg E; Decristoforo C; Andreae F; Zimmer A
    Eur J Pharm Sci; 2019 Nov; 139():105063. PubMed ID: 31487537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.